Portugal Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Portugal Breast Cancer Therapeutics Market Analysis

$ 3999

The Portugal breast cancer therapeutics market is expected to witness growth from $55 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-2030. Major market drivers for Portugal's breast cancer therapeutics market are rising breast cancer cases and newer treatment options available in Portugal. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the main market players in Portugal's breast cancer therapeutics market are Pfizer Portugal, Medivation, and GlaxoSmithKline.

ID: IN10PTPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Portugal AUTHOR: Parul Choudhary

Buy Now

Portugal Breast Cancer Therapeutics Market Executive Analysis

The Portugal breast cancer therapeutics market size is at around $55 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The level of current health spending in Portugal in 2021 increased by 12.2% to reach 11.2% of GDP, the highest level since the series' inception in 2000. The pandemic situation's persistence and the recovery of healthcare providers' activities both contributed to the sharp rise in public and private current spending. Under the COVID-19 special measures, social security assistance was given to healthcare providers totaling $83.5 Mn in 2020. Pay-outs to private ambulatory healthcare providers totaled about 48%. In 2021, an estimated $37.6 Mn was allotted.

In Portugal, breast cancer accounts for roughly 25% of all incidences of cancer in females, making it the most prevalent cancer. Despite an increase in breast cancer cases in Portugal in recent years, the mortality rate has decreased as a result of earlier identification and improved treatment. In order to enhance early identification and treatment of the disease, Portugal developed the National Program for the Fight Against Breast Cancer in 2002. This program offers mammography screening to women 50 to 69 years old as well as breast cancer awareness and self-examination instruction. In Portugal, a lumpectomy or a mastectomy may be used as the first line of treatment for breast cancer. Radiation therapy is frequently used to eradicate any cancer cells that may have survived the surgery. Additionally, breast cancer can be treated with chemotherapy, either in conjunction with or after surgery. Targeted therapy and hormonal therapy are two other popular breast cancer treatments in Portugal. Targeted therapy uses medications that specifically target molecules involved in the growth and spread of cancer cells, whereas hormonal therapy works by preventing the effects of hormones that can feed the growth of cancer cells.

portugal breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

The rise in breast cancer cases in Portugal, which is anticipated to have an impact on the need for novel treatments for breast cancer, is one of the factors driving the growth of the Portugal breast cancer market. Strong immunotherapy uptake and favorable reimbursement are also seen as reliable signs of the market's expansion in Portugal's breast cancer therapeutics.

Market Restraints

Some patients who are unable to afford the expense of therapy in Portugal may have difficulties due to the high cost of breast cancer therapies. Patients, doctors, and healthcare professionals may find the reimbursement procedure for breast cancer therapeutics and medications to be time-consuming and stressful.

Competitive Landscape

Key Players

Hovione (PRT)
Grünenthal (PRT)
AtralCipan (PRT)
Pfizer Portugal (PRT)
Medivation
GlaxoSmithKline
F. Hoffmann-La Roche
Puma Biotechnology
Genentech

Healthcare Policies and Regulatory Landscape

All Portuguese citizens have access to the National Health Service (NHS), which is funded mostly through taxes. Co-payments have been rising over time, and pharmaceutical products have the highest level of cost-sharing. Through Voluntary Health Insurance (VHI). and health subsystems, roughly one-fifth to a quarter of the population has a second set of health insurance coverage. The National Medicines and Health Products Agency (Infarmed) and the Central Directorate of Health (Direço-Geral da Sade, DGS), which is in charge of authorizing drug reimbursement and establishing drug prices, are in charge of managing the reimbursement procedure for cancer medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Portugal Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.